• Soleno Therapeutics Inc SLNO.OQ reported a quarterly adjusted loss of $1.27​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -33 cents. The mean expectation of eight analysts for the quarter was for a loss of $1.15 per share. Wall Street expected results to range from $-1.90 to -65 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Soleno Therapeutics Inc's reported EPS for the quarter was a loss of $1.27​.

• The company reported a quarterly loss of $55.98 million.

• Soleno Therapeutics Inc shares had risen by 1.9% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 7.6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Soleno Therapeutics Inc is $72.50

This summary was machine generated from LSEG data March 4 at 12:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)